Elsevier, Alzheimer's && Dementia :: Translational Research && Clinical Interventions, 1(2), p. 30-44, 2016
DOI: 10.1016/j.trci.2015.12.002
Full text: Download
A straightforward, reproducible blood-based test that predicts age-dependent risk of Alzheimer's disease (AD) could be used as an enrichment tool for clinical development of therapies. This study evaluated the prognostic performance of a genetics-based biomarker risk algorithm (GBRA) established on a combination of apolipoprotein E (APOE)/translocase of outer mitochondrial membrane 40 homolog (TOMM40) genotypes and age, then compare it to cerebrospinal fluid (CSF) biomarkers, neuroimaging, and neurocognitive tests using data from two independent AD cohorts.